Breadcrumb AMCP.org Policy & Advocacy Letters, Statements & Analysis AMCP Joins Stakeholder Group Opposing FDA Update to Biosimilar Naming AMCP Joins Stakeholder Group Opposing FDA Update to Biosimilar Naming 5/18/19 Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page AMCP joins stakeholder group opposing FDA Update to Biosimilar Naming.pdf Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page